Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients With Age-Related Macular Degeneration

NCT03869684 is registered in ClinicalTrials.gov with Senju Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03869684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03869684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients With Age-Related Macular Degeneration
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
February 25, 2019
Completion date
April 24, 2020
Enrollment
13 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration